Our finding may be of importance for treatment of melanomas, as they demonstrate that silencing of Mcl-1 cannot only increase the cytotoxicity of the AdV-TRAIL in TRAIL-resistant melanoma cells but also in TRAIL-sensitive melanoma cells, even when Mcl-1 is expressed at a very low level. This evidence concerns the gene MCL1 and melanoma.